Metabolic Optimization · Reviewed by Ian K. Tseng, MD

What Is Retatrutide? And Why We Do Not Offer It

Retatrutide appears constantly in peptide forums and on gray-market vendor sites, usually described as the next generation of metabolic therapy. The mechanism is genuinely interesting. It is also an investigational compound that has not completed clinical trials and holds no FDA approval in any form — which is why you will not find it on our menu, and why you should be cautious about anyone who will sell it to you.

Published August 4, 2026 · Medical review by Ian K. Tseng, MD, Medical Director

Plain unlabeled laboratory vial on a bare clinical surface, representing a compound Soothe IV does not offer

Not offered by Soothe IV

This is an investigational compound with no FDA approval in any form. We do not prescribe investigational compounds. This article is here because the question deserves a straight answer, not because we are selling anything.

The short answer

Retatrutide is an investigational triple-receptor agonist targeting GIP, GLP-1, and the glucagon receptor. It is in ongoing clinical trials and has no FDA approval for any indication. Soothe IV does not prescribe investigational compounds. Any vendor selling retatrutide today is operating outside the prescription drug framework — typically under a "research use only" label that explicitly disclaims human use.

The mechanism, and why it drew attention

Retatrutide extends the multi-receptor strategy a step further than tirzepatide. Where tirzepatide activates two incretin receptors, retatrutide is designed to activate three: GIP, GLP-1, and the glucagon receptor.

The glucagon receptor is the notable addition. Glucagon is usually discussed as the hormone that raises blood glucose — the counterweight to insulin — which makes it a counterintuitive target. But glucagon receptor agonism also increases energy expenditure, and the design hypothesis is that pairing it with incretin agonism captures that metabolic-rate effect while the GLP-1 and GIP components manage the glucose consequences.

That is a mechanistically elegant idea. It is also, at this point, a hypothesis being tested in trials rather than an established therapy.

Where the evidence actually stands

Retatrutide has produced published Phase 2 results and has advanced into Phase 3 clinical trials. That is a meaningful stage of development, and it is genuinely possible the compound will eventually be approved.

"Eventually possible" is not the same as "available now." Phase 3 exists precisely to characterize efficacy and safety at scale, over time, in a monitored population. Compounds have failed at this stage before, and long-term safety signals are exactly what this phase is designed to surface. Until that process concludes and a regulatory decision follows, the honest description of retatrutide is: promising, unproven, and not a prescription medication.

Why we will not prescribe it

Our program is built on a specific structure: a licensed physician, a Good Faith Examination, required bloodwork, a licensed 503A pharmacy, and ongoing monitoring. Every element of that structure assumes the medication being prescribed exists inside the prescription drug framework.

An investigational compound does not. There is no approved labeling, no established dosing guidance outside the trial protocols, no adverse-event reporting infrastructure for off-trial use, and no pharmacy that can legally dispense it against a prescription. A physician who prescribes it anyway is operating without any of the safety scaffolding that makes physician supervision meaningful in the first place.

If retatrutide completes trials and receives approval, that changes. Until then, the answer is no — and we would rather tell you that plainly than route you to something we do sell.

What "research use only" actually means

Retatrutide is widely available right now from online vendors, labeled "for research use only" or "not for human consumption." That label is not a formality or a legal wink. It is the mechanism by which a seller ships a substance with no medical oversight, no verified purity for human use, no dosing guidance, and no accountability if something goes wrong.

A Certificate of Analysis tells you what is in the vial. It does not tell you whether your body should receive it, at what dose, alongside what else you are taking, or with what monitoring. That gap is the entire distinction between a research chemical and a medical program — a distinction we cover in more depth in are peptides safe?

What is available instead

If metabolic support is the goal, there are compounds inside the prescription framework with established mechanisms, defined dosing, and real safety data. Whether any of them are appropriate for you is a clinical determination made after evaluation and bloodwork — not everyone qualifies, and that is the program working as designed.

You can read about the mechanisms in our explainers on semaglutide and tirzepatide.

Frequently asked questions

Is retatrutide FDA approved?

No. Retatrutide is an investigational compound in ongoing clinical trials. It holds no FDA approval for any indication, in any form. It is not a prescription medication and cannot be legally dispensed by a pharmacy against a prescription.

Why does Soothe IV not offer retatrutide?

Our program requires a licensed physician, a Good Faith Examination, bloodwork, and a licensed 503A pharmacy. An investigational compound has no approved labeling, no established off-trial dosing guidance, and no pharmacy that can legally dispense it. Prescribing it would mean operating without the safety structure that makes physician supervision meaningful. If it completes trials and is approved, that changes.

What does retatrutide do differently from other metabolic compounds?

It is designed to activate three receptors — GIP, GLP-1, and glucagon — rather than one or two. Glucagon receptor agonism increases energy expenditure, and the design hypothesis is that combining it with incretin agonism captures that effect while managing the glucose consequences. This remains a hypothesis under trial investigation rather than established therapy.

Vendors sell retatrutide online. Is that legal?

Those vendors label it "for research use only" or "not for human consumption," which is how a substance ships without medical oversight, verified human-use purity, dosing guidance, or accountability. A Certificate of Analysis confirms what is in the vial; it says nothing about whether your body should receive it, at what dose, or with what monitoring.

Clinical references

Medically reviewed by Ian K. Tseng, MD, Medical Director of Soothe IV's peptide therapy program. The clinical statements in this article are supported by the following sources:

Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023. pubmed.ncbi.nlm.nih.gov
U.S. Food & Drug Administration. The Drug Development Process: Step 3, Clinical Research. www.fda.gov
U.S. Food & Drug Administration. Human Drug Compounding. www.fda.gov

Ready to talk to a physician?

Start your $50 Application. A physician reviews your goals and labs and tells you what — if anything — fits your situation, including when the answer is that peptide therapy is not the right approach. Your fee credits in full toward your first month of membership. Available nationwide.

Book & Pay for Your $50 Application

Serving Orange County, Los Angeles, and San Diego — plus nationwide telehealth. All service areas.

This article is educational and is not medical advice. Statements have not been evaluated by the FDA. Peptide therapy is a physician-supervised medical service; specific protocols are determined individually after a Good Faith Examination and bloodwork, and not all applicants qualify. Some compounded medications used in physician-prescribed protocols are not FDA-approved. Data from clinical trials on FDA-approved medications should not be used to make assessments related to compounded medications. Soothe IV's peptide program is available nationwide via telehealth; prescriptions are issued by physicians licensed in your state.